Academic Journal
Comparative evaluation of a novel card-based spacer (MDI PLUS®) versus traditional aerochamber plus®: In-vivo and ex-vivo bioavailability study.
| Τίτλος: | Comparative evaluation of a novel card-based spacer (MDI PLUS®) versus traditional aerochamber plus®: In-vivo and ex-vivo bioavailability study. |
|---|---|
| Συγγραφείς: | Osama H; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Ammari WG; Department of Pharmacy, Faculty of Health Sciences, American University of Madaba (AUM), Jordan., Sobh AHM; Clinical Pharmacy Department, Faculty of Pharmacy, University of Mashreq, Baghdad, Iraq. Electronic address: ahmed.sobh@uom.edu.iq., Mohsen M; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Boules ME; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Mohamed BME; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Sayed OA; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Abdelrahim MEA; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Saeed H; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt; Clinical Pharmacy Department, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, Ras Sudr, Egypt. |
| Πηγή: | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2025 Sep 01; Vol. 212, pp. 107215. Date of Electronic Publication: 2025 Jul 22. |
| Τύπος έκδοσης: | Journal Article; Randomized Controlled Trial; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Science B.V Country of Publication: Netherlands NLM ID: 9317982 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0720 (Electronic) Linking ISSN: 09280987 NLM ISO Abbreviation: Eur J Pharm Sci Subsets: MEDLINE |
| Imprint Name(s): | Publication: Amsterdam : Elsevier Science B.V Original Publication: Amsterdam ; New York : Elsevier, c1993- |
| Ιατρικοί όροι (MeSH): | Albuterol*/administration & dosage , Albuterol*/urine , Albuterol*/pharmacokinetics , Bronchodilator Agents*/administration & dosage , Bronchodilator Agents*/urine , Bronchodilator Agents*/pharmacokinetics , Metered Dose Inhalers* , Inhalation Spacers*, Lung/metabolism ; Humans ; Biological Availability ; Male ; Adult ; Cross-Over Studies ; Female ; Administration, Inhalation ; Young Adult ; Aerosols ; Middle Aged |
| Περίληψη: | Background: Effective aerosol delivery via pressurized metered dose inhalers (pMDIs) is often compromised by poor actuation-inhalation coordination. Spacer devices are commonly used to improve lung deposition. This study aimed to compare the lung and systemic bioavailability of salbutamol delivered via pMDI alone, with a traditional AeroChamber Plus® spacer, and with a novel disposable MDI Plus® carton spacer. Methods: In a randomized, three-period crossover study, 20 healthy adults received 5 puffs (100 µg/puff) of salbutamol via each inhalation setup. Urine samples were collected 30 min post-inhalation (for lung bioavailability) and over 24 h (for systemic absorption). An ex-vivo setup using inhalation filters was also employed to quantify total delivered dose. Results: The ex-vivo mean ± SD total collected dose of salbutamol was significantly higher with pMDI alone (352.35±23.41 µg) than AeroChamber Plus (196.57±13.32 µg, p < 0.001) and MDI Plus (182.86±11.34 µg, p < 0.001). Urinary salbutamol values at 30 min were significantly greater with AeroChamber Plus (14.61±4.36 µg, p < 0.001) and MDI Plus (10.97±3.83 µg, p < 0.01) compared to pMDI alone (5.92±1.07 µg). Urinary salbutamol at 24 h showed higher systemic bioavailability with pMDI alone (139.09±15.68 µg) versus when connected with both AeroChamber Plus and MDI Plus, 79.57±19.48, and 59.26±18.12 µg, p < 0.001, respectively. Conclusion: Compared to the pMDI alone, both spacers significantly enhanced lung delivery and reduced systemic absorption. Whilst the AeroChamber Plus® delivered slightly more medication to the lung, the MDI Plus® spacer offers a cost-effective alternative that is suitable for emergencies and outdoor use. (Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.) |
| Contributed Indexing: | Keywords: AeroChamber Plus spacer; MDI Plus; Metered dose inhaler; aerosolized therapy; inhaler; salbutamol, pMDI, Spacer, Aerosol delivery, Lung deposition, Respiratory diseases, Asthma care |
| Substance Nomenclature: | QF8SVZ843E (Albuterol) 0 (Bronchodilator Agents) 0 (Aerosols) |
| Entry Date(s): | Date Created: 20250724 Date Completed: 20250825 Latest Revision: 20250826 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.ejps.2025.107215 |
| PMID: | 40706768 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!